AU2005265266B2 - Aequorin-containing compositions and methods of using same - Google Patents

Aequorin-containing compositions and methods of using same Download PDF

Info

Publication number
AU2005265266B2
AU2005265266B2 AU2005265266A AU2005265266A AU2005265266B2 AU 2005265266 B2 AU2005265266 B2 AU 2005265266B2 AU 2005265266 A AU2005265266 A AU 2005265266A AU 2005265266 A AU2005265266 A AU 2005265266A AU 2005265266 B2 AU2005265266 B2 AU 2005265266B2
Authority
AU
Australia
Prior art keywords
aequorin
subject
symptom
calcium
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005265266A
Other languages
English (en)
Other versions
AU2005265266A1 (en
Inventor
Mark Y. Underwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quincy Bioscience LLC
Original Assignee
Quincy Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quincy Bioscience LLC filed Critical Quincy Bioscience LLC
Publication of AU2005265266A1 publication Critical patent/AU2005265266A1/en
Application granted granted Critical
Publication of AU2005265266B2 publication Critical patent/AU2005265266B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
AU2005265266A 2004-06-21 2005-06-21 Aequorin-containing compositions and methods of using same Expired AU2005265266B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/872,795 2004-06-21
US10/872,795 US20060229243A1 (en) 2004-06-21 2004-06-21 Aequorin-containing compositions and methods of using same
PCT/US2005/021770 WO2006010004A2 (en) 2004-06-21 2005-06-21 Aequorin-containing compositions and methods of using same

Publications (2)

Publication Number Publication Date
AU2005265266A1 AU2005265266A1 (en) 2006-01-26
AU2005265266B2 true AU2005265266B2 (en) 2011-05-12

Family

ID=35785748

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005265266A Expired AU2005265266B2 (en) 2004-06-21 2005-06-21 Aequorin-containing compositions and methods of using same

Country Status (20)

Country Link
US (3) US20060229243A1 (enExample)
EP (2) EP1768691B1 (enExample)
JP (1) JP4971150B2 (enExample)
KR (1) KR101213555B1 (enExample)
CN (1) CN1997383B (enExample)
AU (1) AU2005265266B2 (enExample)
BR (1) BRPI0512392B1 (enExample)
CA (1) CA2571542C (enExample)
CY (1) CY1114307T1 (enExample)
DK (1) DK1768691T3 (enExample)
ES (1) ES2422173T3 (enExample)
IL (1) IL180195A (enExample)
MX (1) MXPA06015037A (enExample)
NZ (1) NZ552274A (enExample)
PL (1) PL1768691T3 (enExample)
PT (1) PT1768691E (enExample)
SG (1) SG153848A1 (enExample)
SI (1) SI1768691T1 (enExample)
WO (1) WO2006010004A2 (enExample)
ZA (1) ZA200610688B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060229243A1 (en) * 2004-06-21 2006-10-12 Quincy Resource Group, Inc. Aequorin-containing compositions and methods of using same
GB0625678D0 (en) * 2006-12-21 2007-01-31 Lux Biotechnology Ltd Composition and method for detection of demineralisation
MX2010009753A (es) * 2008-03-11 2010-09-30 Quincy Bioscience Llc Composiciones que contienen apoaecuorina y metodos de uso de las mismas.
JP2010143860A (ja) * 2008-12-19 2010-07-01 Chisso Corp タンパク質の安定化剤
US20110130336A1 (en) * 2009-10-16 2011-06-02 Quincy Bioscience, Llc Method of treating ischemic injury using apoaequorin
WO2012086756A1 (ja) * 2010-12-24 2012-06-28 大塚製薬株式会社 生理活性物質を検出するバイオアッセイ法
SG11201402364WA (en) * 2011-11-15 2014-09-26 Quincy Bioscience Llc Apoaequorin for reducing neuronal injury due to ischemia
GB201700317D0 (en) 2017-01-09 2017-02-22 Calcivis Ltd Detection device
USD1042180S1 (en) 2020-05-28 2024-09-17 Calcivis Limited Dental detection device

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001240855A (ja) * 2000-03-01 2001-09-04 Masashi Sugimoto 生物発光方法及び発光物品

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800492B2 (en) * 2000-06-01 2004-10-05 Institute Pasteur Chimeric GFP-aequorin as bioluminescent Ca++ reporters at the single cell level
US6930169B2 (en) * 2000-06-12 2005-08-16 University Of Baltimore Biotechnology Institute Method of controlling the binding of calmyrin to presenilin
US20060229243A1 (en) * 2004-06-21 2006-10-12 Quincy Resource Group, Inc. Aequorin-containing compositions and methods of using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001240855A (ja) * 2000-03-01 2001-09-04 Masashi Sugimoto 生物発光方法及び発光物品

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D2. AquaLite Recombinant Aequorin (A-6785) Product Information Statement 20-February-2001. *
D3. Yenari M.A et al, "Calbindin D28K Overexpression Protects Striatal Neurons From Transient Focal Cerebral Ischemia" Stroke. 2001, 32:1028-1035 *

Also Published As

Publication number Publication date
CN1997383A (zh) 2007-07-11
EP1768691A4 (en) 2010-08-04
CA2571542A1 (en) 2006-01-26
US20100152117A1 (en) 2010-06-17
KR101213555B1 (ko) 2012-12-18
KR20070070154A (ko) 2007-07-03
BRPI0512392A (pt) 2008-03-11
EP1768691B1 (en) 2013-05-22
HK1109576A1 (en) 2008-06-13
EP2545934A1 (en) 2013-01-16
US20080287350A1 (en) 2008-11-20
MXPA06015037A (es) 2007-07-11
ZA200610688B (en) 2007-12-27
SI1768691T1 (sl) 2013-07-31
IL180195A0 (en) 2007-06-03
JP2008503581A (ja) 2008-02-07
US7671015B2 (en) 2010-03-02
US20060229243A1 (en) 2006-10-12
BRPI0512392B1 (pt) 2022-12-13
JP4971150B2 (ja) 2012-07-11
AU2005265266A1 (en) 2006-01-26
CY1114307T1 (el) 2016-08-31
PL1768691T3 (pl) 2013-09-30
PT1768691E (pt) 2013-06-20
SG153848A1 (en) 2009-07-29
CA2571542C (en) 2014-08-19
DK1768691T3 (da) 2013-07-01
NZ552274A (en) 2010-06-25
EP1768691A2 (en) 2007-04-04
CN1997383B (zh) 2011-01-05
ES2422173T3 (es) 2013-09-09
WO2006010004A2 (en) 2006-01-26
IL180195A (en) 2014-03-31
EP2545934B1 (en) 2014-12-10
WO2006010004A3 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
US20100152117A1 (en) Aequorin-Containing Compositions and Methods of Using Same
CA2717322C (en) Apoaequorin-containing compositions and methods of using same
US12005096B2 (en) Apoaequorin and vitamin d-containing compositions and methods of using same
HK1180974A (en) Aequorin-containing compositions and methods of using same
CA3037892C (en) Apoaequorin and vitamin d-containing compositions and methods of using same
HK1109576B (en) Aequorin-containing compositions and methods of using same
HK1238166A1 (en) Apoaequorin-containing compositions and methods of using same
HK1154217A (zh) 含有脱辅基水母蛋白的组合物及其使用方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired